Kintor Pharmaceutical Limited announced that the company has completed the enrollment of 160 patients for its phase II clinical trial of KX-826 (pyrilutamide) in China for the treatment of acne vulgaris on 14 October 2022. The phase II clinical trial is a randomized, double-blind, placebo-controlled, multi-regional clinical study to evaluate the safety and efficacy of KX-826 (gel) in patients with mild to moderate acne vulgaris. The primary endpoint is the treatment success rate in each group at the end of week 12 (according to the 5-point Investigator Global Assessment (IGA) scale, subjects whose IGA scale decreases by not less than two levels to 0-1 defined as success).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.21 HKD | -0.82% | -11.03% | -25.77% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.77% | 68.66M | |
+9.80% | 118B | |
+10.10% | 106B | |
-11.49% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.61% | 15.97B | |
+6.51% | 14.03B | |
+16.35% | 11.67B |
- Stock Market
- Equities
- 9939 Stock
- News Kintor Pharmaceutical Limited
- Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX 826 for Acne Vulgaris in China